A Chinese company has halted production of an intravenous fluid that may have made 12 children ill in the eastern city of Fuzhou, Bloomberg reported. Zhejiang Juneng Rosi Pharmaceutical withdrew the glucose product while it investigates, according to a statement from parent company Asia Resources Holdings. Initial checks on the intravenous fluid indicate that it wasn’t responsible for the illnesses, Asia Resources said, adding that the children had also received other medication and that users of the fluid elsewhere hadn’t reported problems. The children developed fevers after receiving the fluid at a hospital last week, state media reported. They are now said to be in a stable condition.